Akcea Therapeutics (NASDAQ: AKCA) has promoted Kyle Jenne to chief commercial officer. Jenne joined Boston-based Akea in 2017 as US commercial head. His appointment comes month after a corporate shakeup that led to the departure of three executives. Akcea is working to commercialize inotersen (Tegsedi), a drug approved by the FDA last year as a treatment for the nerves damage caused by the rare disease hereditary transthyretin amyloidosis.
Sponsored · Video
A Fireside Chat with Fish & Richardson Principal Teresa Lavoie
Fish & Richardson
Sponsored · Webinar
Phenotypic Screening & Profiling to Understand a Compound's Disease Impact
Eurofins Discovery
From Our Editors · Podcast
Becoming the Cell & Gene Therapy Hub
